Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Author:
Funder
Institut Curie
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology
Link
http://www.nature.com/articles/s41523-018-0068-4.pdf
Reference12 articles.
1. Cardoso, F. et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann. Oncol. mdw544 (2016). https://doi.org/10.1093/annonc/mdw544
2. Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
3. Piccart, M. et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 25, 2357–2362 (2014).
4. Niraula, S., Ocana, A. & Amir, E. One step forward, two steps back: the story of everolimus in advanced breast cancer. Breast Edinb. Scotl. 24, 529–531 (2015).
5. Diaby, V. et al. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res. Treat. 147, 433–441 (2014).
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer;npj Breast Cancer;2023-03-22
2. Advances in medical treatment of breast cancer in 2022;Cancer Innovation;2023-02
3. Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response;Nature Communications;2021-03-31
4. Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns;Genome Medicine;2020-09-09
5. Simulation of Superconducting Machine With Stacks of Coated Conductors Using Hybrid A-H Formulation;IEEE Transactions on Applied Superconductivity;2020-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3